Medigen Vaccine Biologics (6547) — Capital Reinvestment Ratio
Medigen Vaccine Biologics (6547) has a Capital Reinvestment Ratio of 0.03x as of December 2025, meaning it reinvests 0% of its operating cash flow (NT$101.08 Million) in capital expenditures (NT$3.54 Million). Check tangible net worth ratio of Medigen Vaccine Biologics to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Medigen Vaccine Biologics Capital Reinvestment Ratio (2015–2024)
This chart tracks Medigen Vaccine Biologics's Capital Reinvestment Ratio across 3 annual periods. For the full cash flow conversion analysis, see 6547 operating cash flow.
Annual Capital Reinvestment Ratio for Medigen Vaccine Biologics (2015–2024)
Year-by-year Capital Reinvestment Ratio for Medigen Vaccine Biologics from 2015 to 2024. See 6547 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.86x | NT$40.75 Million | NT$34.98 Million | ▲ +268.8% |
| 2021 | 0.23x | NT$579.89 Million | NT$134.97 Million | ▼ -89.0% |
| 2015 | 2.11x | NT$216.26 Million | NT$457.15 Million | — |